Advanced Cancer
Conditions
Interventions
Experimental group:(1) the patients were selected and treated with ?dt cell infusion for 4 times. The interval of each infusion was 7 days, and the dose of each infusion was 1 × 109 cells According to
Sponsors
Shenzhen Second People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 714/2000 1) patients aged 18-80 years without gender limitation, 2) patients with advanced tumor diagnosed by pathology and imaging, who were rated as C by PG-SGA, 3) patients who had received second-line or above therapy before, 4) expected survival time =3 months, 5) laboratory parameters: A. The criteria of blood routine examination were: HB =70g/l (no blood transfusion within 14 days) , ANC =1.5 × 109/l, PLT =80 × 109/l, lymphocyte (LY)=0.7 × 109/l, LY% =15% , ALB =28G/L, serum lipase and amylase & LT; 1.5 × ULN (upper limit of normal) ;. Biochemical tests were required to meet the following criteria: Tbil =1.5 × ULN (upper limit of normal) ; ALT and AST =2.5 × ULN; ALT and AST =5 × ULN if liver metastases were present; serum CR =2.5 × ULN, endogenous creatinine clearance > GT; 50 ml/min (Cockcroft-gault formula) ; 6) adequate comprehension and voluntary informed consent to participate in clinical studies; 7) women of reproductive age with negative pregnancy tests or male patients who had to use effective and reliable methods of contraception up to 30 days after the end of treatment during the study.
Exclusion criteria
Exclusion criteria: 701/2000 Patients with severe coronary artery disease or pulmonary insufficiency who have hypertension that can not be controlled with medication, unstable heart failure (uncontrolled arrhythmia, unstable angina) , uncompensated congestive heart failure, myocardial infarction within 6 months, current or previous history of brain metastasis or central nervous system invasion, severe active viral or bacterial infection that can not be controlled with treatment, HBV or HCV infection that is serologically positive for HIV or syphilis and is not controlled, immune-related diseases such as autoimmune disease, organ transplantation, or long-term use of immunosuppressive drug such as glucocorticoid, pregnant or lactating women, and any other serious illness that the researchers believe may affect the treatment, follow-up, or evaluation of the patient. It includes any clinically significant neurological, psychiatric, immunomodulatory, metabolic and infectious diseases that have not been controlled, and 9) patients who are not suitable for immune cell therapy after clinical diagnosis and evaluation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| immune function check;quality of life; | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) PG-SGA score;objective response rate (ORR) ;tumor markers;median progression-free survival (PFS);median overall survival (OS); | — |
Countries
China
Contacts
Public ContactXiao Liang
Shenzhen Second People's Hospital
Outcome results
None listed